carboplatin + lapatinib + paclitaxel

This is a combination regimen consisting of three agents—carboplatin, lapatinib, and paclitaxel—used primarily in the treatment of HER2-positive breast cancer. - **Carboplatin** is a platinum-based chemotherapeutic agent that induces DNA crosslinking and apoptosis in rapidly dividing cells. - **Lapatinib** is an oral small-molecule tyrosine kinase inhibitor targeting both epidermal growth factor receptor (EGFR/ERBB1) and human epidermal growth factor receptor 2 (HER2/ERBB2), thereby blocking downstream signaling pathways involved in tumor cell proliferation and survival[7]. - **Paclitaxel** is a taxane-class mitotic inhibitor that stabilizes microtubules, preventing their depolymerization during cell division, leading to apoptosis[8]. The combination has been investigated as neoadjuvant or metastatic therapy for HER2-positive breast cancer patients. Clinical studies have evaluated its efficacy and tolerability; results indicate activity against HER2-overexpressing tumors with manageable toxicity profiles[5][2].

Other names

paclitaxelcarboplatinlapatinib